Adverse Events in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Nationwide, Population-Based, Propensity-Matched Cohort Study
Journal of Clinical Medicine · 27.03.2026 · 15 (7) · 2562
DOI: 10.3390/jcm15072562 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.03.2026. Verfasst von Hyoung Il Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, S…. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BongHwa Scholarship Foundation, BongHwa Scholarship Foundation to the Korean Association for the Study of Intestinal Diseases for 2024.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Safety profiles of advanced therapies (ATs) for inflammatory bowel disease (IBD) may be underestimated in clinical trials due to low event rates and heterogeneous adverse events (AEs).
Methods
Using Korean nationwide claims data (2012–2022), incident IBD patients were identified and classified into AT and non-AT groups. After:1 propensity score matching, risks of tuberculosis (TB), herpes zoster (HZ), and bowel malignancy as primary AEs, and anxiety/depression as secondary AEs, were evaluated.
Results
After matching, 11,205 patients were included in each group. Overall AT use was not associated with a significant increase in TB risk compared with non-AT therapy (hazard ratio [HR] 1.2; p = 0.335), whereas anti–TNF biologics showed higher TB risk (HR 2.0; incidence rate [IR] 100.2 vs. 65.4 per 105 person year [PY]; p < 0.001). AT use was associated with a modestly increased risk of HZ (HR 1.4; IR 2165.8 vs. 2151.3 per 105 PY; p < 0.001), with the highest incidence in small-molecule agents (HR 2.0; IR 4134.2 per 105 PY). The risk of bowel malignancy did not differ between AT and non-AT groups (HR 1.2; p = 0.475). Both anti–TNF and non–anti-TNF biologics were associated with reduced risk of anxiety/depression compared with non-AT therapy (both HR 0.8; p < 0.001 and p = 0.004, respectively).
Conclusions
Overall AT use was not associated with an increased risk of TB, whereas anti–TNF biologics were associated with a higher risk of TB. AT use was also associated with an increased risk of HZ, particularly with small-molecule agents, and a lower risk of anxiety/depression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul 05278, Republic of Korea.
- Center for Trend Monitoring-Risk Modeling, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul 06351, Republic of Korea.
ORCID-Profile: Jung Rock Moon, Jae Myung Cha
Förderung
- BongHwa Scholarship Foundation
- BongHwa Scholarship Foundation to the Korean Association for the Study of Intestinal Diseases for 2024
Zitieren
APA
Choi, H. I., Moon, J. R., Lee, S. H., & Cha, J. M. (2026). Adverse Events in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Nationwide, Population-Based, Propensity-Matched Cohort Study. Journal of Clinical Medicine, 15(7), 2562. https://doi.org/10.3390/jcm15072562
Vancouver
Choi HI, Moon JR, Lee SH, Cha JM. Adverse Events in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Nationwide, Population-Based, Propensity-Matched Cohort Study. Journal of Clinical Medicine. 2026;15(7):2562. doi:10.3390/jcm15072562
BibTeX
@article{Choi2026,
author = {Choi, Hyoung Il and Moon, Jung Rock and Lee, Seon Hwa and Cha, Jae Myung},
title = {Adverse Events in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Nationwide, Population-Based, Propensity-Matched Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {7},
pages = {2562},
doi = {10.3390/jcm15072562}
}
EUVIMED